News on Type_II_Diabetes_Diabetes from BioPortfolio.com http://www.BioPortfolio.com Consolidated Type_II_Diabetes_Diabetes news from BioPortfolio.com Wed, 10 Feb 2010 04:04:32 GMT en XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039316&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039316&THISHREF=http://c.moreover.com/click/here.pl%3fz2538020148%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039316&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039316&THISHREF=http://c.moreover.com/click/here.pl%3fz2538020148%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comXOMA: Older Maternal Age Linked to Incidence of Type 1 Diabeteshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039043&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039043&THISHREF=http://c.moreover.com/click/here.pl%3fz2537889779%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039043&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039043&THISHREF=http://c.moreover.com/click/here.pl%3fz2537889779%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comModern Medicine: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035675&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035675&THISHREF=http://c.moreover.com/click/here.pl%3fz2536327334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035675&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035675&THISHREF=http://c.moreover.com/click/here.pl%3fz2536327334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInterest!ALERT: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034938&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034938&THISHREF=http://c.moreover.com/click/here.pl%3fz2536058499%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034938&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034938&THISHREF=http://c.moreover.com/click/here.pl%3fz2536058499%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034881&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034881&THISHREF=http://c.moreover.com/click/here.pl%3fz2536025209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034881&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034881&THISHREF=http://c.moreover.com/click/here.pl%3fz2536025209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034835&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034835&THISHREF=http://c.moreover.com/click/here.pl%3fz2536001484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034835&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034835&THISHREF=http://c.moreover.com/click/here.pl%3fz2536001484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034679&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034679&THISHREF=http://c.moreover.com/click/here.pl%3fz2535918473%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034679&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034679&THISHREF=http://c.moreover.com/click/here.pl%3fz2535918473%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDMN Newswire: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034573&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034573&THISHREF=http://c.moreover.com/click/here.pl%3fz2535869394%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034573&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034573&THISHREF=http://c.moreover.com/click/here.pl%3fz2535869394%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034567&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034567&THISHREF=http://c.moreover.com/click/here.pl%3fz2535865250%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034567&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034567&THISHREF=http://c.moreover.com/click/here.pl%3fz2535865250%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034558&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034558&THISHREF=http://c.moreover.com/click/here.pl%3fz2535860585%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034558&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034558&THISHREF=http://c.moreover.com/click/here.pl%3fz2535860585%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGlobeNewswire via Yahoo!: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034539&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034539&THISHREF=http://c.moreover.com/click/here.pl%3fz2535845600%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034539&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034539&THISHREF=http://c.moreover.com/click/here.pl%3fz2535845600%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStockwatch: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034532&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034532&THISHREF=http://c.moreover.com/click/here.pl%3fz2535841609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034532&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034532&THISHREF=http://c.moreover.com/click/here.pl%3fz2535841609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsBlaze: XOMA (XOMA) Begins Enrollment for XOMA 052 Phase 2bhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034901&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034901&THISHREF=http://c.moreover.com/click/here.pl%3fz2536032150%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034901&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034901&THISHREF=http://c.moreover.com/click/here.pl%3fz2536032150%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034607&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034607&THISHREF=http://c.moreover.com/click/here.pl%3fz2535881134%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034607&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034607&THISHREF=http://c.moreover.com/click/here.pl%3fz2535881134%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGlobeNewswire via MSN Money: Cell transplants offer best hope for diabetes curehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038064&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038064&THISHREF=http://c.moreover.com/click/here.pl%3fz2537463817%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038064&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Type_II_Diabetes_Diabetes&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038064&THISHREF=http://c.moreover.com/click/here.pl%3fz2537463817%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comThe Province: